Nominations for the 2019 eyeforpharma awards are currently open.
In a world where true value matters and trust is critical; what are we rewarding?
It’s time for pharma to show its true colors and provide the maximum value to the greatest number of patients.
As we transform our industry, it’s vital to support the best work - and support it today, in 2019.
Nominations are now open for the eyeforpharma Awards 2019 - Click HERE to find out more.
We have 13 categories including new awards that celebrate innovation, disruption, entrepreneurs and pioneers.
How are you adding value? Find out how you can reward and be rewarded - Click HERE to find out more.
Categories include:
• New: Most Promising Pilot
This award is for an experimental initiative which has the potential to disrupt the status quo.
• New: Most Valuable Education/Awareness Initiative
This award is for an initiative that has raised the profile and visibility of a disease, cause, health concern, population or treatment.
• New: Most Valuable Data & Insights Initiative
This award is for an initiative that harnesses data (internal or RWD), AI, ML or analytics to reveal valuable insights, ultimately resulting in new opportunities for better patient care.
• Most Valuable Healthcare/HCP Initiative
The winner of this award will be an innovative project which has delivered tangible working and healthcare improvements, both in the long and short term, to healthcare professionals.
• Most Valuable Collaboration
The winner of this award will be the creator of a pharma-pharma or pharma-non pharma initiative which clearly brings a new proposition to either HCPs, payers and/or healthcare systems.
Download your Entry Pack here to find out more.
If you have any questions about the eyeforpharma Awards 2019, email Liz Swift at eswift@eyeforpharma.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.